Lipids for pharmaceutical applications from Merck
Lipids are the most commonly used delivery method for RNA therapeutics and vaccines, and lipid nanoparticles could prove a game changer for COVID-19 and many other diseases.
Lipids for passive and active targeting
Surface modification on liposomes is a very effective method to control their physical and biological behaviors. Specific receptor antigens such as antibodies, peptides or sugar moieties can make liposomes preferentially target certain tissues or cell types. Such immunoliposomes are used in both, therapeutic and diagnostic applications. The targeted lipids could also be modified with antigens for immunological applications.
Merck has patents/ licenses and deep knowledge to make lipid conjugates, that could be utilized for active targeting.
For passive targeting, Merck offers PEGylated lipids that could be used for long circulating liposomes.
Your global partner for the manufacturing of synthetic lipids
A GMP-scalable process which yields a high-quality lipid is essential to lipidic drug product development and manufacturing. Merck is highly specialized in synthesizing top-quality GMP lipids for pharmaceutical applications and gene therapy, focusing on tailored manufacturing to meet your specific needs. Merck also offers an off-the-shelf catalog with optimized stability, solubility, and handling characteristics. If lipid blends are needed, they can provide lyophilization and spray drying. For formulation support, contact them.
Merck’s sites all over the world, including Western Europe, meet the high regulatory demands for the manufacture of synthetic lipids, using ICH Q7-compliant quality systems. Committed to consistently high product quality, reliability of supply, and short delivery timelines, they assist you through all phases of clinical development and commercialization and help you meet your development milestones.
Merck manufactures portfolio lipids, PEGylated lipids, cationic/ ionizable lipids, and targeted lipids.